Joining us today is Dr. Shankar Musunuri, the co-founder, chairman, and CEO of Ocugen, Inc., a biotechnology company that develops vaccines for public health and gene and cell therapies to treat eye diseases. Dr. Musunuri brings over 30 years of experience to the Ocugen team. Prior to co-founding Ocugen, he held senior leadership roles at several companies, and spent nearly 15 years at Pfizer. In this interview, Dr. Musunuri discusses some of Ocugen’s innovative advances. Their first product, a modifier gene therapy platform, is currently undergoing Phase I trials. Ocugen’s second program will reach clinics next year and targets age-related macular degeneration, which affects nine to 10 million Americans.
Facing elimination, the Philadelphia 76ers took to their home court after a thrilling stand in…
The Bus Revolution plan has been finalized, and SEPTA’s board, which previously put off a…
The Philadelphia 76ers are back home in Philly to take on the New York Knicks…
The Philadelphia 76ers off-court strategy heading into Game 6 of their NBA playoff series is…
The one highlight the Philadelphia Eagles chose to broadcast of Will Shipley after they drafted…
The Philadelphia Eagles haven’t always been a premier franchise in the NFL. After years of…
This website uses cookies.